

ANALYSIS OF REVERSE HYBRID TOTAL HIP REPLACEMENT USING THE CORAIL® FEMORAL COMPONENT IN THE NATIONAL JOINT REGISTRY FOR ENGLAND, WALES, NORTHERN IRELAND AND THE ISLE OF MAN

Jack Mantel, Medical Affairs Manager | *DePuy Synthes Joint Reconstruction*
John Leopold, Biostatistician | *DePuy Synthes Joint Reconstruction*

Introduction

National joint registries provide valuable and generalizable information on the revision rates / survivorship of newer and older implants alike. Typically they include large cohorts with contributions from all surgeons, irrespective of experience level. The National Joint Registry for England and Wales (UK NJR) has been in operation since 2003 and in that time has collected data on over 708,000 total hip replacements. A reverse hybrid total hip replacement (THR) uses a cemented all-polyethylene acetabular cup and uncemented femoral stem. Up to the end of 2014, reverse hybrid THR accounted for 17,267 procedures on the NJR, with a steady uptake in adoption from just 0.6% in 2003 to 3.0% in 2014.¹

Lindalen et al² analysed 3,963 reverse hybrid THRs recorded on the Norwegian Arthroplasty Registry in a ten year period between 2000 and 2009. In this cohort there were 3553 (89.7%) implantations of the CORAIL stem with six different cemented cup systems. The results were then compared with those from the 10 most common cemented implant combinations over the same follow-up period. The authors found no statistical difference in implant survivorship at 5 and 7 years between the reverse hybrid group and the cemented combinations. This was also the case in patients younger than 60 when the survivorship analysis was adjusted for age. In a study based on data from the New Zealand Joint Registry, Hooper et al³ compared the patient time incidence rates (PTIR) across four fixation types. The reverse hybrid cohort demonstrated similar or lower revision rates as compared to cemented, cementless or standard hybrid fixation, although the cohort size was far smaller than the other groups. McNally et al⁴ studied survival of the Furlong HA coated femoral stem in combination with a cemented polyethylene cup at 10–11 years and found survivorship of 99% for the stem and 95% for the cup. The AOA NJRR does not report results for reverse hybrid procedures as a class.

The purpose of this analysis is to examine the results of the CORAIL femoral implant when used in reverse hybrid THR. In addition to the publicly available UK NJR reports, data is also available from a Supplier Feedback dataset, downloaded by DePuy Synthes from the UK NJR on 10th January 2016.⁵ This additional information provides detailed data on all CORAIL implantations included on the registry. The focus of this commentary is the combination of CORAIL stems with either the ELITE PLUS™ or MARATHON® XLPE all-polyethylene cemented acetabular cups. Sub-analysis has been performed on different head materials and sizes.

Demographics

In total the dataset records 5671 cases in which a CORAIL stem has been implanted with an ELITE PLUS cemented cup, and 7369 cases in which a MARATHON XLPE cemented cup has been used. The demographics are tabulated below.

Cup	N	Mean Age	Age Range	Female	Male
CORAIL/ELITE PLUS	5671	71.69	16-101	3694 (65%)	1977 (35%)
CORAIL/MARATHON	7369	69.89	18-97	4575 (62%)	2794 (38%)

Table 1: CORAIL Reverse Hybrid THR: Cohort demographics split by Cemented Cup. (2016 NJR)

Results

The follow up for the ELITE PLUS group extends to 10 years and the PTIR for this group is 0.34 (95% CI 0.27, 0.41). In the MARATHON XLPE group the maximum follow up is 7 years and the PTIR is 0.28 (95% CI 0.21, 0.35). The system allows for multiple reasons for revision to be entered. These are tabulated below in Table 2 and the cumulative incidence rates of the most prevalent reasons for revision have been plotted in Figure 1 for each cup group.




Figure 1: CORAIL Reverse Hybrid THR: Cumulative revision rates split by Cemented Cup. (2016 NJR)




Figure 2: CORAIL Reverse Hybrid THR: Cumulative incidence rate of revision reasons split by Cemented Cup. (2016 NJR)

Reason	CORAIL/ ELITE PLUS	CORAIL/ MARATHON
Dislocation/Subluxation	27	15
Aseptic Loosening - Stem	22	13
Infection	21	14
Pain	15	2
Peri-Prosthetic Fracture - Stem	15	6
Aseptic Loosening - Socket	8	
Malalignment - Stem	6	3
Wear of Acetabular Component	4	
Malalignment - Socket	3	2
Other	3	6
Lysis - Stem	2	
Adverse Soft Tissue Reaction to Particulate Debris	1	1
Head/Socket Mismatch - Socket	1	1
Head/Socket Mismatch MDS2	1	
Implant Fracture - Stem	1	
Lysis - Socket	1	2
Peri-Prosthetic Fracture - Socket	1	
Dissociation of Liner		1

Table 2: CORAIL Reverse Hybrid THR: Revision reasons split by Cemented Cup. (2016 NJR)

Kaplan-Meier analysis was undertaken to estimate the cumulative revision rate (CRR) with an end point of revision of any component for any cause. Table 4 includes the cumulative revision rate estimates for the overall cohorts, plus the estimates for the different head materials. The cohort sizes are such that reliable estimates are not possible for all the head size/material combinations.

Group	1 year	3 years	5 years	7 years	10 years
CORAIL/ELITE PLUS n=5671	0.49% (0.34, 0.71%) n=5216	1.20% (0.94, 1.54%) n=4054	1.78% (1.43, 2.22%) n=2789	2.18% (1.75, 2.70%) n=1602	3.93% (2.34, 6.53%) n=90
CORAIL/ELITE PLUS Metal Heads n=3857	0.58% (0.39, 0.89%) n=3516	1.11% (0.81, 1.52%) n=2654	1.74% (1.32, 2.29%) n=1774	2.03% (1.54, 2.67%) n=1040	3.56% (1.87, 6.73%) n=74
CORAIL/ELITE PLUS Ceramic Heads n=1770	0.29% (0.12, 0.70%) n=1656	1.34% (0.88, 2.05%) n=1358	1.84% (1.26, 2.69%) n=980	2.46% (1.72, 3.51%) n=543	n/a
CORAIL/MARATHON n=7369	0.42% (0.29, 0.60%) n=5870	0.90% (0.68, 1.20%) n=3031	1.12% (0.84, 1.49%) n=1192	1.30% (0.95, 1.78%) n=88	n/a
CORAIL/MARATHON Metal Heads n=4942	0.43% (0.28, 0.67%) n=3925	0.84% (0.59, 1.20%) n=2092	1.03% (0.72, 1.48%) n=840	1.29% (0.87, 1.93%) n=63	n/a
CORAIL/MARATHON Ceramic Heads n=2402	0.40% (0.21, 0.77%) n=1920	1.04% (0.65, 1.368%) n=918	1.33% (0.82, 2.15%) n=336	n/a	n/a

Table 3: CORAIL Reverse Hybrid THR: Cumulative revision rate estimates split by Cemented Cup and head material. (2016 NJR) (95% CI), N with later follow up⁵

Summary

The National Joint Registry results for the combinations of CORAIL stems with both ELITE PLUS and MARATHON cups compare favourably within the class of reverse hybrid THR as reported on the NJR.⁶ The 7-year cumulative revision rate for the CORAIL/MARATHON combination from the Supplier Feedback dataset is 1.30% (95%CI 0.95, 1.78%) and the 10-year cumulative revision rate for the CORAIL/ELITE Plus combination is 3.93% (95%CI 2.34, 6.56%). From the NJR Annual Report the cumulative revision rate for all reverse hybrid THR is 2.80% (95%CI 2.42, 3.22%) at 7 years and 4.18% (95%CI 3.23, 5.40%) at 10 years. The Norwegian registry study² reported cumulative revision rates for Reverse Hybrid THR of 3.3% (95%CI 2.6, 4.0) at 5 years and 4.6% (95%CI 3.3, 5.6%) at 7 years.

Conclusion

The proponents of reverse hybrid THR claim that the approach is advantageous as it removes the challenges of femoral cementing technique and saves operating time⁷. These advantages can be combined with the excellent long-term results of all-polyethylene cemented cups to provide a long-term solution with excellent survivorship over the mid to long-term^{2,4}. The introduction of moderately cross-linked polyethylene may further improve the results of the cemented all-polyethylene cups due to a reduction in wear^{8,9}. Cumulative revision rate estimates have been calculated from the NJR dataset on the combination of the CORAIL femoral stem with both the ELITE PLUS and the MARATHON cemented cups. The revision rate estimates of the CORAIL femoral stem with both the ELITE PLUS and the MARATHON cemented cups are low, and compare favourably to the overall class of reverse hybrid THR from the NJR⁶, the New Zealand Joint Registry³ and the Norwegian Arthroplasty Register.²

References

1. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, 12th Annual Report, 2015. Table 3.3. Available from: www.njrreports.org.uk.
2. Lindalen E, Havelin L, Nordsletten L, Dybvik E, Fenstad A, Hallan G, Furnes O, Høvik Ø, Röhrli S. Is reverse hybrid hip replacement the solution? 3,963 primary hip replacements with cemented cup and uncemented stem, from the Norwegian Arthroplasty Register. *Acta Orthopaedica* 2011; 82 (6): 639–645
3. Hooper GJ, Rothwell AG, Stringer M, Frampton C. Revision following cemented and uncemented primary total hip replacement - A Seven-Year Analysis from the New Zealand Joint Registry. *J Bone Joint Surg Br.* 2009;91(4):451-8
4. McNally SA, Shepperd JAN, Mann CV, Walczak JP. The results at nine to twelve years of the use of a hydroxyapatite-coated femoral stem. *J Bone Joint Surg Br.* 2000;82(3):378-82.
5. NJR-NJR data from 1st April 2003 -10th January 2016 on DePuy-Synthes products supplied for post-marketing surveillance, NJR Centre, 2016.
Notes: NJR-NJR Supplier Feedback data do not include Hospital Episode Statistics (HES) Data Linkage. Revision may therefore be underreported.
6. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, 12th Annual Report, 2015. Table 3.7. Available from: www.njrreports.org.uk
7. Alho A, Lepistö J, Ylinen P, Paavilainen T. Cemented Lubinus and Furlong total hip endo-prosthesis: a 12-year follow-up study of 175 hips comparing the cementing technique. *Arch Orthop Trauma Surg.* 2000;120:276–280
8. Engh CA Jr, Hopper RH Jr, Huynh C, Ho H, Sritulanondha S, Engh CA Sr. A prospective, randomized study of cross-linked and non-cross-linked polyethylene for total hip arthroplasty at 10-year follow-up. *J Arthroplasty.* 2012;27(8 Suppl):2-7.e1.
9. Young-Hoo Kim, Jang-Won Park, Chirag Patel, Dae-Youn Kim. Polyethylene Wear and Osteolysis After Cementless Total Hip Arthroplasty with Alumina-Highly Cross-Linked Polyethylene Bearings in Patients Younger Than Thirty Years of Age. *J Bone Joint Surg Am.* 2013;95:1088-93.

All analysis was carried out by DePuy Synthes, the NJR do not vouch for the accuracy of the interpretation.

The third-party trademarks used herein are trademarks of their respective owners.



Johnson & Johnson Medical Limited PO BOX 1988, Simpson Parkway, Livingston, West Lothian, EH54 0AB, United Kingdom.
Incorporated and registered in Scotland under company number SC132162.

DePuy Orthopaedics, Inc.
700 Orthopaedic Drive
Warsaw, IN 46582
USA
Tel: +1 (800) 366 8143
Fax: +1 (574) 267 7196

DePuy International Ltd
St Anthony's Road
Leeds LS11 8DT
England
Tel: +44 (0)113 270 0461
Fax: +44 (0)113 272 4101

DePuy (Ireland)
Loughbeg
Ringaskiddy
Co. Cork
Ireland
Tel: +353 21 4914 000
Fax: +353 21 4914 199



depuysynthes.com

©Johnson & Johnson Medical Limited. 2016. All rights reserved.

CA#DSEM/JRC/0416/0631 Issued: 04/16